Barclays PLC Purchases 36,071 Shares of Paysign, Inc. (NASDAQ:PAYS)

Barclays PLC increased its position in Paysign, Inc. (NASDAQ:PAYS) by 327.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,090 shares of the company’s stock after acquiring an additional 36,071 shares during the period. Barclays PLC’s holdings in Paysign were worth $173,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PAYS. SG Americas Securities LLC purchased a new position in Paysign in the third quarter worth about $43,000. Algert Global LLC bought a new position in shares of Paysign in the 2nd quarter worth approximately $46,000. The Manufacturers Life Insurance Company purchased a new position in shares of Paysign in the second quarter worth approximately $66,000. American Century Companies Inc. bought a new stake in Paysign during the second quarter valued at approximately $92,000. Finally, Bard Associates Inc. purchased a new stake in Paysign during the third quarter valued at approximately $103,000. Hedge funds and other institutional investors own 25.89% of the company’s stock.

Paysign Price Performance

Shares of NASDAQ:PAYS opened at $2.90 on Wednesday. The company has a market capitalization of $155.29 million, a P/E ratio of 19.33 and a beta of 0.95. Paysign, Inc. has a 1-year low of $2.40 and a 1-year high of $5.59. The firm’s 50 day simple moving average is $3.35 and its two-hundred day simple moving average is $3.99.

Paysign (NASDAQ:PAYS) last released its earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. Paysign had a net margin of 14.28% and a return on equity of 30.64%. The company had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $14.96 million. During the same quarter in the previous year, the company earned $0.02 EPS. On average, sell-side analysts anticipate that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Barrington Research reiterated an “outperform” rating and set a $7.00 price target on shares of Paysign in a research note on Monday, November 4th. Lake Street Capital started coverage on Paysign in a research report on Friday, December 20th. They set a “buy” rating and a $6.00 target price on the stock.

Insider Activity

In other Paysign news, insider Matthew Louis Lanford sold 25,360 shares of Paysign stock in a transaction on Friday, November 8th. The shares were sold at an average price of $3.96, for a total value of $100,425.60. Following the sale, the insider now directly owns 109,731 shares in the company, valued at approximately $434,534.76. The trade was a 18.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Mark Newcomer sold 36,000 shares of the stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $3.66, for a total transaction of $131,760.00. Following the transaction, the chief executive officer now directly owns 9,336,886 shares of the company’s stock, valued at $34,173,002.76. This trade represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 668,465 shares of company stock worth $2,187,249 over the last ninety days. Corporate insiders own 23.40% of the company’s stock.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.